These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. Jarosławski S; Toumi M BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092 [TBL] [Abstract][Full Text] [Related]
24. Special report: vaccines for the treatment of prostate cancer. Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182 [No Abstract] [Full Text] [Related]
25. [Promising on advanced cancer, several new drugs coming]. Widmark A; Karlsson CT Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668 [No Abstract] [Full Text] [Related]
26. A prostate cancer 'vaccine' under development. Mayo Clin Health Lett; 2009 Dec; 27(12):4. PubMed ID: 20082492 [No Abstract] [Full Text] [Related]
27. Advanced clinical states in prostate cancer. Cheng HH; Lin DW; Yu EY Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531 [TBL] [Abstract][Full Text] [Related]
28. Degarelix (firmagon) for prostate cancer. Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145 [No Abstract] [Full Text] [Related]
35. How does sipuleucel-T alter our clinical practice? George D BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691 [No Abstract] [Full Text] [Related]
36. [Castration resistant prostate cancer 2011]. Miller K Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832 [TBL] [Abstract][Full Text] [Related]
37. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]